



Virtual CCRC 2021 Scientific Program

All times are listed in Eastern Time.

Monday, November 8, 2021				
12:00 - 12:15	Welcome and Opening Remarks			
12:15 - 1:45	Keynote Session and Panel Discussion - Personalizing Big Data			
1:45 - 2:00	Break			
2:00 - 2:15	LS 1A - Lightning Session and Discussion - Palliative Care	ORAL 1A - Concurrent Session with Q&A - Tumour Microenvironment and Immunology	ORAL 1B - Concurrent Session with Q&A - Cancer Clinical Trial Approaches	Engagement Session - Indigenous-Led Research & Data Governance in Cancer Control
2:15 - 2:30				
2:30 - 2:45	LS 1B - Lightning Session and Discussion - Health Services and Policy			
2:45 - 3:00				
3:00 - 3:15	Break			
3:15 - 3:30	LS 1C - Lightning Session and Discussion - Blood Cancer	ORAL 1C - Concurrent Session with Q&A - Immunotherapy	ORAL 1D - Concurrent Session with Q&A - Indigenous Cancer Research	
3:30 - 3:45				
3:45 - 4:00	LS 1D - Lightning Session and Discussion - Pancreatic Cancer			
4:00 - 4:15				
4:15 - 4:30	End of day wrap up			



Tuesday, November 9					
12:00 - 12:15	Welcome and Opening Remarks				
12:15 - 1:45	Keynote Session and Panel Discussion - Aging Well with Cancer				
1:45 - 2:00	Break				
2:00 - 2:15	LS 2A - Lightning Session and Discussion - Breast Cancer	LS 2B - Lightning Session and Discussion - Brain Cancer	ORAL 2A - Concurrent Session with Q&A - Precision Medicine and Biomarkers	ORAL 2B - Concurrent Session with Q&A - Patient Reported Outcomes and Patient Experience	Workshop - Ethical Research with First Nations, Inuit and Métis
2:15 - 2:30					
2:30 - 2:45	LS 2C - Lightning Session and Discussion - Colorectal Cancer	LS 2D- Lightning Session and Discussion - Lung Cancer			
2:45 - 3:00					
3:00 - 3:15	Break				
3:15 - 3:30	LS 2E - Lightning Session and Discussion - Pediatric Cancer	LS 2F - Lightning Session and Discussion- Rare Cancers	ORAL 2C - Concurrent Session with Q&A - Metastasis	Concurrent Session - Cancer Research Platforms	
3:30 - 3:45					
3:45 - 4:00	LS 2G - Lightning Session and Discussion - Prostate Cancer	LS 2H - Lightning Session and Discussion - Ovarian Cancer			
4:00 - 4:15					
4:15 - 4:30	End of day wrap up				



Wednesday, November 10					
12:00 - 12:15	Welcome and Opening Remarks				
12:15 - 12:30	LS 3A - Lightning Session and Discussion - Synthetic Lethality	ORAL 3A - Concurrent Session with Q&A - COVID-19 and Cancer Screening and Treatment	ORAL 3B - Concurrent Session with Q&A - Lifestyle and Diet		
12:30 - 12:45					
12:45 - 1:00	LS 3B - Lightning Session and Discussion - Liver metastasis				
1:00 - 1:15					
1:15 - 1:30	Break				
1:30 - 3:00	Keynote Session and Panel Discussion - Tomorrow's Cancer Therapies Today				
3:00 - 3:15	Break				
3:15 - 3:30	LS 3C - Lightning Session and Discussion - Bioinformatics and Genomics	ORAL 3C - Concurrent Session with Q&A - Metabolism	ORAL 3D - Concurrent Session with Q&A - Equity in Cancer Care		
3:30 - 3:45					
3:45 - 4:00	LS 3D - Lightning Session and Discussion - DNA Damage and Repair				
4:00 - 4:15					
4:15 - 4:30	End of day wrap up				



Thursday, November 11					
12:00 - 12:15	Welcome and Opening Remarks				
12:15 - 12:30	LS 4A - Lightning Session and Discussion - Chemoresistance	ORAL 4A - Concurrent Session with Q&A - Epigenetics	ORAL 4B - Concurrent Session with Q&A - Imaging and Radiation Oncology		
12:30 - 12:45					
12:45 - 1:00	LS 4B - Lightning Session and Discussion - Geriatric Oncology				
1:00 - 1:15					
1:15 - 1:30	Break				
1:30 - 1:45	LS 4C - Lightning Session and Discussion - Prevention	ORAL 4C - Concurrent Session with Q&A - Patient Engagement	ORAL 4D - Concurrent Session with Q&A - Bioinformatics and AI		
1:45 - 2:00					
2:00 - 2:15	LS 4D - Lightning Session and Discussion - Cancer Risk and Primary Prevention				
2:15 - 2:30					
2:30 - 2:45	Break				
2:45 - 4:15	Keynote Session and Panel Discussion - Understanding and Managing Risk - The saga of hereditary cancer				
4:15 - 4:30	CCRC 2021 Wrap Up				



Monday, November 8, 2021

12:00 – 12:15 pm

Welcome and Opening Remarks

12:15 – 1:45 pm

Keynote Session and Panel Discussion – Personalizing Big Data

Moderators:

Dr. Claudia Kleinman
McGill University, Lady Davis Institute

Dr. Don Desserud
Patient Partner

Dawn of Digital Pathology: Leveraging AI for Cancer Biomarker Discovery

Dr. Ali Bashashati
University of British Columbia, Vancouver Coastal Health Research Institute

Using Big Data to advance Precision Medicine in Oncology: Opportunities and Challenges

Dr. Hermann Nabi
Social and Preventive Medicine, Université Laval

PROFYLE: The Canadian Pediatric Precision Oncology Initiative

Dr. Rebecca Deyell
Pediatrics, University of British Columbia

1:45 – 2:00 pm

Break

2:00 – 3:00 pm

ORAL 1A - Concurrent Session with Q&A - Tumour Microenvironment and Immunology

Chairs:

Dr. Paola Marcato
*Dalhousie University, Beatrice Hunter
Cancer Research Institute*

Mrs. Heather Hogan
Patient Partner

Investigating Intra-Tumour Metabolic Heterogeneity in Triple-Negative Breast Cancer

Marina Fukano
McGill University

Harnessing synthetic lethality to drive ferroptosis in hypoxic solid tumours

Dr. Shawn Chafe
BC Cancer Research Institute

Cancer cell plasticity leads to the activation of progenitor-like signaling pathways and immune checkpoint genes

Dr. Iacovos Michael
Sunnybrook Research Institute



ORAL 1B -Concurrent Session with Q&A - Cancer Clinical Trial Approaches

Chairs:

Dr. Madeline Li
*University Health Network, Princess
Margaret Cancer Centre*

Ms. Nathalie Baudais
Patient Partner

The Rethinking Clinical Trials (REaCT) program: leading pragmatic, practice-changing, patient-centred research across Canada

Dr. Mark Clemons
Ottawa Hospital

PAROLE-Onco, accompanying patients as members of the care team: mirage or reality?

Dr. Marie-Pascale Pomey
Centre de recherche du CHUM

Protocol for implementing a national exercise oncology program: Project EXCEL

Dr. S. Nicole Culos-Reed
University of Calgary

ENGAGEMENT SESSION - Indigenous-Led Research & Data Governance in Cancer Control: Acknowledging the Heart, Spirit & Mind of Indigenous Data

Facilitator:

Melissa Cernigoy
Canadian Partnership Against Cancer

Indigenous-led research and data governance in cancer control is an emerging area of science that requires specialized knowledge and expertise. For example, current gaps in Indigenous cancer research and data systems exist within Canada while little exploration has been done to summarize existing promising practices in Indigenous cancer control data and research. In response, the Canadian Partnership Against Cancer is working with the an Indigenous Team, including the Alberta First Nations Information Governance Centre to undertake an environmental scan and engage relevant stakeholders on a regional, national and international scale. The project is designed to address the following aims:

1. To inform the implementation of the CPAC 2022-2027 Business Plan to be responsive to new and existing partner needs and aligning actions with the health system for FNIM governed research and data systems
2. To synthesize and integrate the key findings of the environmental scan engagement components for people-specific Indigenous governed research data systems and promising practices in cancer control data and research

This presentation will meet the following 3 objectives:

1. Provide an overview of the project, including guiding questions and primary activities
2. Present key findings from the environmental scan of published literature, Indigenous-led research, and relevant organizational reports, documents and frameworks
3. Discuss a holistic Indigenous model developed for data and information synthesis and interpretation grounded in Indigenous knowledge and conceptualizations of heart, spirit and mind

Dr. Angeline Letendre
Canadian Indigenous Nurses Association, Alberta Health Services

Ms. Lea Bill
Canadian Indigenous Nurses Association



2:00 – 2:30 pm

LS 1A - Lightning Session and Discussion - Palliative Care

The PROVIEW+ tool: Validating a cancer model to predict risk of death, poor performance status and severe symptoms over time

Dr. Hsien Seow
McMaster University

Using stakeholder engagement to inform Canadian Cancer Society's position statement on medical assistance in dying (MAiD)

Ms. Ruhi Kiflen
Canadian Cancer Society

Acceptability of Automatic Referrals to Supportive and Palliative Care by Patients Living with Advanced Lung Cancer: A Co-Design Process

Dr. Aliyah Pabani
University of Calgary

Does early palliative care reduce end-of-life healthcare costs: A population-based, propensity-score matched cohort study

Dr. Hsien Seow
McMaster University

Palliative home care and emergency department visits in the last 30 and 90 days of life: a retrospective cohort study of cancer patients

Ms. Jennifer Mracek
University of Calgary

2:30 – 3:00 pm

LS 1B - Lightning Session and Discussion - Health Services and Policy

The Use of Risk-Sharing Agreements to Reimburse High-Cost Oncology Drugs: Legal, Regulatory and Policy Considerations

Melanie McPhail
Simon Fraser University

Lung cancer care in Saskatchewan and Ontario: An interprovincial analysis of patient characteristics and survival outcomes

Mr. Dmitry Neymark
University of Saskatchewan

Preliminary evaluation results of the integrated knowledge translation approach utilized in the Canadian Population Attributable Risk of Cancer (ComPARE) study

Apiramy Jeyapalan
Canadian Cancer Society

The use of complementary medicine among individuals with cancer: Standardizing assessment and documentation and evaluating prevalence and associations of use

Dr. Lynda Balneaves
University of Manitoba

Characterizing the financial burden of advanced cancer: interim analysis of financial effects data from people living with advanced colorectal cancer

Dr. Marc Kerba
University of Calgary

3:00 – 3:15 pm

Break



3:15 – 4:15 pm

ORAL 1C - Concurrent Session with Q&A - Immunotherapy

Chairs:

Dr. Shashi Gujar
Dalhousie University

Ms. Chantale Thurston
Patient Partner

The spatial immune landscape of cutaneous melanoma

Dr. Ian Watson
Goodman Cancer Research Centre, McGill University

Targeting CXCR2-mediated neutrophil recruitment to non-small cell lung cancer

Mr. Simon Milette
McGill University

Elucidating the Role of the non-Receptor Tyrosine Kinase Fes in Tumour Immune Evasion

Mr. Brian Laight
Queen's University

ORAL 1D - Concurrent Session with Q&A - Indigenous Cancer Research

Chairs:

Dr. Brenda Elias
University of Manitoba

Ms. Louise Bird
Patient Partner

Re-conceptualizing Metrics for an Indigenous Cancer Indicator Framework on Cancer Screening to Early Diagnosis and through the Cancer Journey

Dr. Angeline Letendre
Canadian Indigenous Nurses Association

Exploring the cancer experiences and outcomes for Metis patients and families in Saskatchewan

Mr. Adel Panahi and Miss Tegan Brock
Metis Nation - Saskatchewan

The Manitoba Metis Cancer Journey

Ms. Julianne Sanguins
Manitoba Metis Federation

3:15 – 3:45 pm

LS 1C - Lightning Session and Discussion - Blood Cancer

Transient receptor potential vanilloid type calcium channel (TRPV6) as a novel therapeutic target in lymphoid tumours

Dr. Alli Murugesan
University of New Brunswick

Molecular Subtyping of NPM1 mutated AML

Dr. Arvind Mer
Princess Margaret Cancer Centre

Defining the biological significance and role of somatic TMEM30A mutations in diffuse large B cell lymphoma.

Shannon Healy
BC Cancer Agency

A modular activatable synthetic biology system to visualize in vivo cell-cell communication

Mr. TianDuo Wang
Robarts Research Institute

Mathematical modelling of perturbed hematopoiesis during the pre-leukemic phase of AML to evaluate therapeutic strategies for clonal reduction

Mia Brunetti
Université de Montréal



3:45 – 4:15 pm

LS 1D - Lightning Session and Discussion - Pancreatic Cancer

Exploring the effects of SBRT on the pancreatic tumor microenvironment using intravital fluorescence microscopy

Mr. Timothy Samuel
University Health Network

TANDEM: Biomicrofluidic Systems with Transverse And Normal Diffusional Environments for Multidirectional Signalling

Mr. Michael Mohan
University of Toronto

The Role of Neutrophil Extracellular Trap/CCDC25/Integrin Linked Kinase in Pancreatic Ductal Adenocarcinoma (PDAC) Progression and Metastasis

Dr. Paul McDonald
BC Cancer Research Institute

4:15 – 4:30 pm

End of Day Wrap Up

Tuesday, November 9, 2021

12:00 – 12:15 pm

Welcome and Opening Remarks

12:15 – 1:45 pm

Keynote Session and Panel Discussion – Aging Well with Cancer

Moderators:

Dr. Martine Puts
University of Toronto

Ms. Debi Lascelle
Patient and Family Representative

Telomeres in Cancer and Aging

Dr. Ronald DePinho
MD Anderson Cancer Center

Aging well during and after cancer therapies

Dr. Shabbir Alibhai
Medicine, University Health Network

Working with older adults as they manage cancer: Evidence & opportunities

Dr. Kristen Haase
School of Nursing, University of British Columbia

Dignity and Personhood in the Terminally Ill

Dr. Harvey Chochinov
University of Manitoba

1:45 – 2:00 pm

Break



2:00 – 3:00 pm

ORAL 2A - Concurrent Session with Q&A - Precision Medicine and Biomarkers

Chairs:

Dr. Elena Kuzmin
Concordia University, McGill University

Dr. Christine Wu
Patient Partner

From cell signaling to drug targeting in melanoma

Dr. Ian Watson
Goodman Cancer Research Centre, McGill University

Deciphering intra-tumoral heterogeneity in multiple myeloma: A single cell study

Dr. Ali Mahdipour Shirayeh
University of Toronto

The receptor for hyaluronan-mediated motility as a regulator of drug sensitivity in triple-negative breast cancer

Ms. Britney Messam
Western University

ORAL 2B - Concurrent Session with Q&A - Patient Reported Outcomes and Patient Experience

Chairs:

Dr. Lynn Gauthier
*Research-Centre of the CHU de Québec,
Cancer Research Centre, Université Laval*

Ms. Donna Pepin
Patient Partner

Harnessing the Power of Integrated Patient Reported Outcomes (PROs): Exploring the Relationship Between Symptom Complexity and Health System Utilization

Dr. Linda Watson
Alberta Health Services

Cancer Journey Experiences of Métis Albertans

Ms. June Kima
The Métis Nation of Alberta

Experiences and Perceptions of Older Adults with Lower-risk Hormone Receptor-positive Breast Cancer about Adjuvant Radiotherapy and Endocrine Therapy: A Patient Survey

Dr. Marie-France Savard
University of Ottawa

WORKSHOP - Ethical Research with First Nations, Inuit and Métis

Facilitator:

Dr. Sara Urowtiz
Canadian Cancer Research Alliance, Canadian Partnership Against Cancer

Sponsored by:



Join this “fireside chat” to gain a better understanding about how researchers and Indigenous community leaders engage in health/cancer-related research that is ethical and benefits First Nations, Inuit and Métis. Three panelists will share their thoughts, experiences and opinions on how they have built ethical research partnerships, included diverse perspectives in their research and are guided by First Nations, Inuit and Métis research principles and protocols.

Mr. Adel Panahi
Métis Nation – Saskatchewan

Dr. Gary Groot
University of Saskatchewan

Dr. Jennifer Shea
Memorial University



2:00 – 2:30 pm

LS 2A - Lightning Session and Discussion - Breast Cancer

Emergence of B1 integrin-deficient mammary tumors from dormancy involves both epithelial cell intrinsic and extrinsic mechanisms	Miss Yu Gu <i>McGill University</i>
Developing a model of HER2+/ER+ breast cancer to examine the role of the immune microenvironment on therapeutic response	Miss Hailey Dall-Proud <i>McGill University</i>
Inhibiting the adaptor protein ezrin enhances adaptive anti-tumor immune responses in a mouse model of triple-negative breast cancer	Dr. Victoria Hoskin <i>Queen's University</i>
Using Machine Learning to Identify Risk Factors for Severe Vasomotor Symptoms in Breast Cancer Patients	Dr. Katherine Cole <i>University of Ottawa</i>
Dissecting novel ShcA-regulated signalling networks that promote breast cancer progression and therapeutic resistance.	Miss Kathryn Hunt <i>McGill University</i>

LS 2B - Lightning Session and Discussion - Brain Cancer

Regulation of mRNA translation by eIF5B in glioblastoma	Dr. Nehal Thakor <i>University of Lethbridge</i>
Invasive growth of brain metastases is driven by cancer cell-pSTAT3+ reactive astrocyte crosstalk	Ms. Sarah Maritan <i>McGill University</i>
Cell Cycle Regulation as a Permissive Early Event During Gliomagenesis	Dr. Lisa Porter <i>University of Windsor</i>
Glioblastoma Temozolomide Chemoresistance: Is Autophagy Playing a Role?	Miss Courtney Clark <i>University of Manitoba</i>
The Role of RNA Methyltransferase NSUN5 in Translational Reprogramming and Tumorigenesis in Glioblastoma	Yan Shu Kong <i>University of Alberta</i>

2:30 – 3:00 pm

LS 2C - Lightning Session and Discussion - Colorectal Cancer

A systematic review of colorectal cancer prevention and screening interventions among Indigenous populations in Canada and abroad	Ms. Eleeyah Uri <i>Ontario Health</i>
Evaluation of algorithms using administrative health and structured electronic medical record data to determine breast and colorectal cancer recurrence in a Canadian province	Mr. Pascal Lambert <i>CancerCare Manitoba</i>
Treatment patterns and survival outcomes of early age-at-onset colorectal cancer patients in Alberta: a population-based study	Dr. Dylan O'Sullivan <i>University of Calgary</i>



Genomic instability and DNA damage regulate STING activation through characteristic cytosolic DNA structures in colorectal cancer

Shayla Mosley
University of Alberta

Analyzing tumour infiltrating lymphocyte populations in MSI vs. MSS primary colon cancer patients using digital cytometry

Ms. Sara Pietropaolo
Dalhousie University

LS 2D - Lightning Session and Discussion - Lung Cancer

Création et caractérisation d'une cohorte provinciale de patients atteints d'un cancer du poumon à l'aide de données clinico-administratives

Mr. Gino Boily
Institut d'excellence en santé et en services sociaux

Examining the Relationship Between Green Space, Air Pollution, and Lung Cancer Incidence Using Bayesian Hierarchical Modelling.

Mr. Jonathan Simkin
BC Cancer

Perspectives of family physicians towards access to lung cancer screening for individuals living with low income

Dr. Ambreen Sayani
Women's College Hospital

Infrared Spectroscopic Analysis of Exhaled Breath for Prediction of Progression-Free and Overall Survival in Lung Cancer Patients

Ms. Erin Brooks
Dalhousie University

Non-small cell lung cancer survival by immigrant status: A population-based retrospective cohort study in Ontario, Canada

Dr. Geetanjali Datta
Cedars-Sinai Medical Centre

3:00 – 3:15 pm

Break

3:15 – 4:15 pm

ORAL 2C - Concurrent Session with Q&A - Metastasis

Chairs:

Dr. Amina Zoubeidi
University of British Columbia

Ms. Cathie Hays
Patient Partner

3D Chromatin Remodeling Potentiates Transcriptional Programs Driving Cell Invasion

Dr. Michael Witcher
The Lady Davis Institute of McGill University

Proteomic screens for suppressors of anoikis identify IL1RAP as a promising surface target in Ewing sarcoma

Dr. Haifeng Zhang
University of British Columbia

Neutrophil oxidative stress mediates obesity-associated vascular inflammation and metastatic transmigration

Sheri McDowell
McGill University



Concurrent Session – Cancer Research Platforms

Chairs:

Ms. Kimberly Badovinac
Canadian Cancer Research Alliance, Canadian Partnership Against Cancer

The Canadian Tissue Repository Network CTRNet; update on biospecimen and data resources and tools to help cancer researchers

Dr. Anne-Marie Mes-Masson
Centre de recherche du CHUM

Dr. Peter Watson
BC Cancer

CanPath: A national platform for health research

Dr. Trevor Dummer
University of British Columbia

Networked Support for Canada's Academic Cancer Trial Environment

Mr. Stephen Sundquist
3CTN - Canadian Cancer Clinical Trials Network

Marathon of Hope Cancer Centres Network and Digital Health and Discovery Platform

Mr. Stephen Herst
Terry Fox Research Institute

Dr. Bryce Pickard
Digital Health and Discovery Platform

3:15 – 3:45 pm

LS 2E - Lightning Session and Discussion - Pediatric Cancer

Hearing Loss in Cisplatin-Treated Childhood Cancer Patients is Mediated by Toll-Like Receptor 4

Ms. Asna Latif
University of Alberta

Potential pro-leukemic signaling through Toll-like receptor 3 in pediatric acute lymphoblastic leukemia

Ms. Tanmaya Atre
BC Children's Hospital Research Institute

Understanding and preventing acute lymphoblastic leukemia late adverse effects using genomics and machine learning

Mr. Nicolas Raymond
Université de Sherbrooke

Genetic and Transcriptional analysis of Patient-Derived Xenografts (PDXes) for Leptomeningeal Disease

Miss Ana Isabel Castillo Orozco
McGill University, RI-MUHC

LS 2F - Lightning Session and Discussion- Rare Cancers

STING Activation in Sarcoma: Assessing Clinically Relevant Therapeutic Strategies

Ms. Karys Hildebrand
University of Calgary

Development of targeted radioimmunotherapy for osteosarcoma using comparative oncology approach

Mr. Chandra Bose Prabaharan
University of Saskatchewan

Characterization of metabolic rewiring and identification of potential therapeutic targets in CBFA2T3-GLIS2-dependent AMKL

Dr. Caroline Capdevielle
Centre de recherche HMR

Tumorigenic properties of uveal melanoma cancer cells grown in 3D or on a reconstructed extracellular matrix

Oliver Chancy
Université Laval



Alterations on intracellular localization and trafficking of the RET receptor induced by Multiple Endocrine Neoplasia type 2 mutations

Mr. Eduardo Reyes-Alvarez
Queen's University

3:45 – 4:15 pm

LS 2G - Lightning Session and Discussion - Prostate Cancer

Clinical and genomic indolence in lung recurrent metastatic hormone-sensitive prostate cancer

Dr. Nicolette Fonseca
University of British Columbia

Identifying Circulating Genes to Stratify Patients with Advanced Prostate Cancer and Predict Therapeutic Response

Miss Seta Derderian
RI-MUHC

Identification of Cellular Signatures Predictive of Human Prostate Cancer Progression

Ms. Chloe Liu
McGill University, Goodman Cancer Research Centre

The role of receptor tyrosine kinase ROR2 in stemness and immune evasion

Ms. Nakisa Tabrizian
University of British Columbia / Vancouver Prostate Centre

The gut microbiome-prostate tumour crosstalk is modulated by dietary polyunsaturated fatty acids

Mr. Jalal Laaraj
Centre de recherche du CHU de Québec-Université Laval

LS 2H - Lightning Session and Discussion - Ovarian Cancer

Targeting NAD metabolism counters PARP inhibitor resistance in ovarian cancer

Mr. Alex Sauriol
Institut du cancer de Montreal

Cystathionine gamma lyase: A promising therapeutic target in clear cell carcinoma of the ovary

Dr. Amal EL-Naggar
University of British Columbia

Development of theranostic probes against MUC16 to enable PET/CT imaging for early detection and targeted radioimmunotherapy of MUC16 expressing ovarian cancers.

Miss Hanan Babeker
University of Saskatchewan

Oviduct epithelial cells constitute two developmentally distinct lineages that are spatially separated along the distal-proximal axis

Dr. Matthew Ford
McGill University, Goodman Cancer Research Centre

Developing an ovarian cancer tissue cell fate (TCFate) manipulation and detection tool

Miss Marie Orléan ADA NDONG
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM)

4:15 – 4:30 pm

End of Day Wrap Up



Wednesday, November 10, 2021

12:00 – 12:15 pm

Welcome and Opening Remarks

12:15 – 1:15 pm

ORAL 3A - Concurrent Session with Q&A - COVID-19 and Cancer Screening and Treatment

Chairs:

Dr. Timothy Hanna
Queen's University

Ms. Melissa Coombs
Patient Partner

Predicted impact of the COVID-19 pandemic on cancer incidence and mortality in Canada

Dr. Talía Malagón
McGill University

Utilization of COVID-19 related funding modifications for systemic cancer therapies in Ontario, Canada

Ms. Jaclyn Beca
Ontario Health

Evaluating the impact of the COVID-19 pandemic on new cancer diagnoses and oncology care in Manitoba

Dr. Kathleen Decker
CancerCare Manitoba, University of Manitoba

ORAL 3B - Concurrent Session with Q&A - Lifestyle and Diet

Chairs:

Dr. P. Peter Wang
University of Toronto

Mr. Archie Stewart
Patient Partner

Psychiatric Disorder Incidence Among Adolescents and Young Adults Aged 15-39 with Cancer: A Population-Based Cohort Study

Dr. Miranda Fidler-Benaoudia
University of Calgary

The Association of Estimated Cardiorespiratory Fitness and Overweight and Obesity with Invasive Breast Cancer: A prospective cohort study

Miss Rebecca Christensen
University of Toronto

Investigating the relationship between heavy metal exposure and cancer risk in Canada

Miss Katherine Pulella
University of Toronto

12:15 – 12:45 pm

LS 3A - Lightning Session and Discussion - Synthetic Lethality

Preclinical Studies on Novel Treatment Plans for Metastatic Triple Negative Breast Cancers

Dr. Armin Gamper
University of Alberta, Cross Cancer Institute

Genome-Wide CRISPR Cas9 Screen Reveals a Synthetic Lethal Interaction Between PARG and PTEN in Melanoma

Mr. Emmanuel Asante
McGill University



**Genome-wide CRISPR Screens Identify Ferroptosis as a Novel
Therapeutic Vulnerability in Acute Lymphoblastic Leukemia**

Dr. Marie-Eve Lalonde
National Research Council

The roles of 4E-BP1 in breast cancer metastasis

Mr. Predrag Jovanovic
Lady Davis Institute

Characterizing the role of ETFDH on cancer biology

Dr. David Papadopoli
Lady Davis Institute

12:45 – 1:15 pm

LS 3B - Lightning Session and Discussion - Liver Metastasis

**The role of Estrogen in the Immune Microenvironment of Liver
Metastases**

Miss Yasmine Benslimane
McGill University

**Immunoprofiling the Impact of Treatments on Co-opting Histological
Growth Patterns of Colorectal Cancer Liver Metastases**

Diane Kim
McGill University Health Centre

**EV derived Proteomics profile to stratify Angiogenic and Non-
Angiogenic HGPS in Colorectal Cancer Liver metastasis**

Mrs. Migmar Tsamchoe
Research Institute of McGill University Health Centre

**A comprehensive analysis of SNPs and CNVs in relation to survival
outcomes in colorectal cancer**

Mr. Yajun Yu
Memorial University of Newfoundland

1:15 – 1:30 pm

Break

1:30 – 3:00 pm

Keynote Session and Panel Discussion - Tomorrow's Cancer Therapies Today

Moderators:

Dr. Madhuri Koti
Queen's University

Ms. Ruth Ackerman
Patient and Family Representative

Single-cell sequencing for identifying lung cancer biomarkers

Dr. Paola Marignani
Biochemistry and Molecular Biology, Dalhousie University

Clinical Applications of Liquid Biopsy in Oncology

Dr. Lillian Siu
University Health Network

**From the Clinic to the Lab: Investigating Mechanisms of Response and
Resistance to Immune Checkpoint Therapy**

Dr. Padmanee Sharma
MD Anderson Cancer Centre



3:00 – 3:15 pm

Break

3:15 – 4:15 pm

ORAL 3C - Concurrent Session with Q&A – Metabolism

Chairs:

Dr. Rachel Murphy
University of British Columbia

Mr. Angus Pratt
Patient Partner

Mevalonate metabolism as an actionable vulnerability of t(4;14)-positive multiple myeloma

Dr. Joseph Longo
Van Andel Institute

Metabolic adaptations supporting the evolution of resistance to chemotherapeutics in breast cancer

Mr. Yannick Audet-Delage
University of Ottawa

Targeting metabolism as a novel therapeutic strategy to suppress oncogenic MYC in group 3 medulloblastoma tumors

Emma Martell
University of Manitoba

ORAL 3D - Concurrent Session with Q&A - Equity in Cancer Care

Chairs:

Dr. Erin Strumpf
McGill University

Ms. Mei-Lin Yee
Patient Partner

Building on Existing Tools to Improve Chronic Disease Prevention and Screening in Public Health: A Cluster Randomized Trial

Dr. Aisha Lofters
Women's College Hospital

Exploring Health Equity in a Context of Cancer Prevention from Alberta Métis Perspectives

Dr. Angeline Letendre
Canadian Indigenous Nurses Association

High prevalence of triple negative and quadruple negative breast cancer among women of African ancestry compared to Caucasian women

Shawn Hercules
McMaster University

3:15 – 3:45 pm

LS 3C - Lightning Session and Discussion - Bioinformatics and Genomics

Circulating-tumour DNA Derived Nucleosome Positioning Captures Tissue Gene Expression And Transcription Factor Activity In Prostate Cancer

Ms. Xinyi Chen
Vancouver Prostate Centre

In-silico selection of potential overexpressed cancer protein markers in blood plasma samples

Dr. Huiyan Li
University of Guelph



Application of Generalized Multifactor Dimensionality Reduction (GMDR) methods to identify potential multi-SNP interactions associated with survival times in colorectal cancer patients

Mr. Aaron Curtis
Memorial University of Newfoundland

Orchestrating and sharing large multimodal biomedical data for more transparent and reproducible biomarker discovery

Dr. Benjamin Haibe-Kains
University Health Network

LDCT Lung Sub-cm Nodule Malignancy Prediction with Combination Radiomics and Machine Learning Models

Mr. Ian Janzen
BC Cancer

3:45 – 4:15 pm

LS 3D - Lightning Session and Discussion - DNA Damage and Repair

Investigation of the sexual dimorphic tumor suppressor role of DDX3X in melanoma

Mrs. Marine Lingrand
McGill University

High sensitivity of p53 mutated sonic hedgehog medulloblastoma to ATM inhibition

Mrs. Niusha Khazaei
McGill University

The role of HORMAD1 in DNA damage repair in squamous cell carcinomas

Mrs. Jennifer Gantchev
McGill University

Revival Stem Cells Mediate P53-Dependent DNA Repair to Regenerate the Intestinal Epithelium

Dr. Arshad Ayyaz
Mount Sinai Hospital

Beyond BRCA1 during DNA repair by homologous recombination (HR): characterization of the zinc finger protein POGZ as a novel pro-HR factor

Dr. Alexandre Orthwein
Lady Davis Institute

4:15 – 4:30 pm

End of Day Wrap Up

Thursday, November 11, 2021

12:00 – 12:15 pm

Welcome and Opening Remarks



12:15 – 1:15 pm

ORAL 4A - Concurrent Session with Q&A – Epigenetics

Chairs:

Dr. Gareth Williams
University of Calgary

Dr. Rosilene Kraft
Patient Partner

MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets

Dr. David Labbé
McGill University

Uncovering the dosage-dependent roles of Arid1a in gastric tumorigenesis for combinatorial drug therapy

Mr. Adrian Loe
Hospital for Sick Children

Systematic characterization of the bromodomain containing subunits within the mSWI/SNF chromatin remodeling complexes

Miss Lynda AGBO
Université Laval

ORAL 4B - Concurrent Session with Q&A - Imaging and Radiation Oncology

Chairs:

Dr. Nawaid Usmani
University of Alberta

Ms. Katey Thompson
Patient Partner

Predicting Prostate Cancer Response to Brachytherapy Using AI Driven Digital Pathology

Dr. Calum MacAulay
BC Cancer

Ionizing radiation upregulates TKS5 expression in Glioblastoma

Ms. Lisa Decotret
BC Cancer

Anti-hypertensive Drug Modulates Cancer-Associated Fibroblasts to Improve Radiation Response

Ms. Che-Min Lee
BC Cancer Research Centre

12:15 – 12:45 pm

LS 4A - Lightning Session and Discussion – Chemoresistance

Overcoming cancer recurrence and metastatic progression by targeting anastasis

Dr. Wells Brown
British Columbia Cancer Research Institute

Identify Targetable Molecular Drivers of Chemotherapy Resistance in Gastro-Esophageal Adenocarcinoma

Ms. Iris Kong
McGill University

SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca²⁺ flux to mitochondria

Miss Kangning Yang
McGill University

Reciprocal metabolic and epigenetic adaptations to microenvironment stress exposes vulnerabilities in breast cancer

Ms. Geneviève Deblois
Université de Montréal

Immune checkpoint inhibitor resistance mutations in the IFN-JAK-STAT pathway increase melanoma sensitivity to oncolytic virus treatment

Dr. Ian Watson
Goodman Cancer Research Centre, McGill University



12:45 – 1:15 pm

LS 4B - Lightning Session and Discussion - Geriatric Oncology

Identifying gaps in the care of older Albertans with cancer: Analysis of patient-reported, clinical, administrative, and survey datasets	Dr. Fay Strohschein <i>University of Calgary</i>
Prevalence of Preexisting Cognitive Impairment in Patients Treated for Cancer and Its Impact on Cognitive Outcomes	Nelly Toledano <i>University of Toronto</i>
Care Provided by Older Adult Caregivers to a Spouse in Active Cancer Treatment: A Scoping Review	Mrs. Valentina Donison <i>University of Toronto</i>
Comprehensive geriatric assessment and management for Canadian elders with Cancer: the 5C study	Dr. Martine Puts <i>University of Toronto</i>
Self-management interventions for issues identified in a geriatric assessment: a systematic review	Mrs. Valentina Donison <i>University of Toronto</i>

1:15 – 1:30 pm

Break

1:30 – 2:30 pm

ORAL 4C - Concurrent Session with Q&A - Patient Engagement

Chairs:

Dr. David Dawe
CancerCare Manitoba, University of Manitoba

Ms. Michelle Stratton
Patient Partner

The top ten research priorities for early stage colorectal cancer: A Canadian patient oriented priority setting partnership

Dr. Colleen Cuthbert
University of Calgary

Real-world implementation of an electronic patient-reported outcomes program in cancer centres in Quebec (e-IMPAQc): successes, challenges, and lessons learned

Dr. Sylvie Lambert
McGill University

Operationalizing Patient Identified Priorities in the Breast Cancer Community

Ms. Diana Ermel and Ms. Jenn Gordon
Canadian Breast Cancer Network

ORAL 4D - Concurrent Session with Q&A - Bioinformatics and AI

Chairs:

Dr. Franco Vizeacoumar
*Saskatchewan Cancer Agency,
University of Saskatchewan*

Ms. Kirsten Efremov
Patient Partner

Meta-analysis of preclinical pharmacogenomics studies for biomarker discovery

Dr. Benjamin Haibe-Kains
University Health Network



Evolution of large copy number variants in breast cancer through genetic network rewiring

Dr. Elena Kuzmin
McGill University

Multi-omic classification and characterization of pancreatic neuroendocrine neoplasms

Dr. Sharon Gorski
BC Cancer

1:30 – 2:00 pm

LS 4C - Lightning Session and Discussion – Prevention

Mental Health Disorders, Cancer Risk, and the Mediating Role of Health Behaviours in the CARTaGENE Cohort Study

Miss Kaitlyn Gilham
The University of British Columbia

A population-based study of salpingectomy and risk of epithelial ovarian cancer in Ontario

Mr. Vasily Giannakeas
Women's College Hospital

Long working hours and prostate cancer risk: results from a population-based case-control study

Miss Charlotte Salmon
*Institut national de la recherche scientifique - Centre Armand-Frappier
Santé Biotechnologie*

Synergistic effects of combined inflammatory cytokines IFN γ , IL1 β , TNF α , and TGF β , on the proliferation and gene expression of breast cancer cells

Mr. Jorge Alfonso Leon Machado
Université de Sherbrooke

Dietary antioxidant formulation reduces carcinogen-induced DNA damage in bronchial epithelial cells in vitro

Dr. Jose Merlin Jayaraj
Dalhousie University

2:00 – 2:30 pm

LS 4D - Lightning Session and Discussion – Cancer Risk and Primary Prevention

Effets de pesticides agricoles sur le transcriptome de cellules cancéreuses

Miss Nadia Côté
Université de Sherbrooke

Sleep duration and ovarian cancer risk

Mrs. Flavie Marquis
Université de Montréal

Omega-3 fatty acids and inflammatory markers expression in normal breast tissue

Dr. Kaoutar Ennour-Idrissi
Laval University

Quality of life for men at risk of prostate cancer: a descriptive analysis from a large Canadian cohort

Ms. Roxane Tourigny
CHU de Québec, Université Laval

UVR on skin tissues induce the retrotransposon LINE-1 expression reactivation

Miss Marine Lambert
Research Institute of MUHC



2:30 – 2:45 pm

Break

2:45 – 4:15 pm

Keynote Session and Panel Discussion - Understanding and Managing Risk - The saga of hereditary cancer

Moderators:

Dr. Jacque Simard
*Centre de recherche du CHU de Quebec,
Université Laval*

Ms. Nathalie Baudais
Patient and Family Representative

The cellular specificity of hereditary cancers syndromes: two short stories

Dr. David Huntsman
BC Cancer, University of British Columbia

The Saga of Hereditary Cancer 1987 to 2021

Dr. Steven Narod
Women's College Research Institute

Family Histories and Hereditary Cancer Services: minimizing the bottleneck and opening the bottle

Dr. Nadine Caron
University of Northern British Columbia

4:15 – 4:30 pm

CCRC 2021 Wrap Up